Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $750 million aggregate principal amount of 3.250% notes due 2023 and $650 million aggregate principal amount of 3.625% notes due 2028, guaranteed by Roche Holding Ltd.

Headquartered in Basel, Switzerland, the Roche Group is a leading research-based health care group with combined strengths in pharmaceuticals and diagnostics as well as expertise in molecular biology. It operates in more than 100 countries and employs more than 93,700 people worldwide.

The Davis Polk corporate team included partners John Banes and Leo Borchardt and associates Andrew Rowe, Christopher T. Diel and Grace M. Cao. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Members of the Davis Polk team are based in the London and New York offices.

Copy link to share post